We are live on ! Find out more
CG

Carlyle Group Portfolio holdings

AUM $10.6B
1-Year Est. Return 11.25%
This Fund
S&P 500
This Quarter Est. Return
+5.93%
1 Year Est. Return
+11.25%
3 Year Est. Return
-0.47%
5 Year Est. Return
-4.92%
10 Year Est. Return
+7.54%
AUM
$2.08B
AUM Growth
-$226M
Cap. Flow
-$304M
Cap. Flow %
-14.63%
Top 10 Hldgs %
96.3%
Holding
26
New
1
Increased
2
Reduced
2
Closed
1

Top Buys

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$16.1M
2
SPWR icon
SunPower Inc
SPWR
+$338K
3
SYRE icon
Spyre Therapeutics
SYRE
+$133K

Top Sells

Rank Stock Value
1
MKSI icon
MKS Inc
MKSI
+$301M
2
GTM
ZoomInfo Technologies
GTM
+$17.8M
3
GETY icon
Getty Images
GETY
+$1.65M

Sector Composition

Rank Sector Weight
1 Healthcare 57.36%
2 Technology 33.33%
3 Consumer Staples 4.75%
4 Communication Services 2.37%
5 Real Estate 1.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MKSI icon
26
MKS Inc
MKSI
$21.9B
– –
-3,482,732
Closed -$301M
1
2

Similar funds

SGA
Sustainable Growth Advisers Stamford, Connecticut $10.6B AUM 2.6% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
BMSSC
B. Metzler seel. Sohn & Co Frankfurt, Germany $10.8B AUM 21.99% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
HTC
Haverford Trust Company Radnor, Pennsylvania $10.9B AUM 18.64% 1-Year Est. Return
CA
Clearstead Advisors Cleveland, Ohio $10.9B AUM 18.41% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return

Carlyle Group's Q4 2023 Portfolio in Review

As of Q4 2023, Carlyle Group held 26 positions worth $2.08B, down 9.8% from $2.31B the previous quarter. Its ten largest holdings account for 96% of the portfolio.

Carlyle Group withdrew a net $304M in Q4 2023, closing 1 position and reducing 2 holdings. Its most notable exit was MKS Inc, an estimated $301M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 57% of assets, up from 49% a quarter earlier, followed by Technology and Consumer Staples.

Against the trend, Carlyle Group opened a new position in Spyre Therapeutics worth $204K.

  • Carlyle Group's largest Q4 2023 buy was Spyre Therapeutics: 9,620 shares worth $204K.
  • Carlyle Group added most to Soleno Therapeutics in Q4 2023, an estimated $16.1M increase.
  • Carlyle Group's biggest Q4 2023 reduction was ZoomInfo Technologies, cutting an estimated $17.8M.
  • Carlyle Group fully exited MKS Inc in Q4 2023, selling an estimated $301M.
  • Carlyle Group's ten largest holdings make up 96% of its $2.08B portfolio in Q4 2023.
  • Carlyle Group opened 1 new position and closed 1 in Q4 2023.
  • Carlyle Group's portfolio value fell 9.8% quarter-over-quarter to $2.08B.

Based on Carlyle Group's 13F filing for Q4 2023, filed 2 Feb 2024.